You can now read 10 articles a month for free. Read as much as you want anywhere and anytime for just 99¢.

Red Sox Live

6

2

Final

2 Sanofi drug patents invalidated

WASHINGTON - Sanofi’s two patents on the cancer drug Taxotere were ruled invalid and unenforceable by a federal court Monday in a victory for two makers of generic drugs, Hospira Inc. and Apotex Inc.

The US Court of Appeals for the Federal Circuit upheld a lower court finding on the two patents.

Continue reading below

Taxotere, the successor to the cancer drug Taxol, generated $1.2 billion last year for Paris-based Sanofi. That was a 57 percent drop from the year before because of generic-drug competition, Sanofi said Feb. 8.

The Federal Circuit, which specializes in patent cases, said a judge was correct to rule the two patents were obvious variations of earlier research, and that the inventor misled the Patent and Trademark Office to obtain the patents by withholding that earlier know-how.

Sanofi is evaluating its legal options, a spokeswoman said. Hospira said that it was pleased with the decision.

“Hospira is committed to continuing to provide US cancer patients with high-quality, lower-cost alternatives,’’ said a spokesman.

Loading comments...

You have reached the limit of 10 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week